---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-130419"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:26:08.010443+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Sensei Biotherapeutics FY2025 net loss $21.1M; advances PIKTOR with $200M private placement

## Summary
- Net loss of $21.1M, or $(16.72) per share, compared to $30.2M loss in prior year.
- Cash and marketable securities $21.2M at Dec 31, 2025, down from $41.3M at Dec 31, 2024.
- Completed acquisition of Faeth Therapeutics; adds oral PIKTOR candidate targeting PI3K/AKT/mTOR.
- Concurrent $200M private placement supports Phase 2 endometrial and Phase 1b breast cancer trials.
- Topline data from Phase 2 endometrial and start of Phase 1b breast cancer expected by year-end 2026.

## SEC filing metadata
- accession: 0001193125-26-130419
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312526130419/0001193125-26-130419-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312526130419/d118677d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-130419
- JSON: https://secwatch.observer/filing/0001193125-26-130419.json
- Plain text: https://secwatch.observer/filing/0001193125-26-130419.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.